Receptor Life Sci 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cannabidiol Technosphere (cannabidiol inhalation powder) / Receptor Life Sci
ACTRN12621001365853: A study of RLS103 (CBD-Technosphere® Inhalation Powder) in Healthy Adult Volunteers

Completed
1
30
 
Receptor Life Sciences Australia Pty Ltd, Receptor Life Sciences Australia Pty Ltd
Panic Disorder , Social Anxiety Disorder
 
 
NCT05429788: Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

Withdrawn
1
40
US
Low dose RLS103, High dose RLS103, placebo inhaled dry powder
Receptor Life Sciences
Social Anxiety Disorder
11/22
11/22
NCT05678881: Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

Terminated
1
2
NA
High dose RLS103, placebo inhaled powder, Low dose RLS103
Receptor Life Sciences, The Epilepsy Study Consortium
Epilepsy
02/24
02/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cannabidiol Technosphere (cannabidiol inhalation powder) / Receptor Life Sci
ACTRN12621001365853: A study of RLS103 (CBD-Technosphere® Inhalation Powder) in Healthy Adult Volunteers

Completed
1
30
 
Receptor Life Sciences Australia Pty Ltd, Receptor Life Sciences Australia Pty Ltd
Panic Disorder , Social Anxiety Disorder
 
 
NCT05429788: Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

Withdrawn
1
40
US
Low dose RLS103, High dose RLS103, placebo inhaled dry powder
Receptor Life Sciences
Social Anxiety Disorder
11/22
11/22
NCT05678881: Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

Terminated
1
2
NA
High dose RLS103, placebo inhaled powder, Low dose RLS103
Receptor Life Sciences, The Epilepsy Study Consortium
Epilepsy
02/24
02/24

Download Options